201 related articles for article (PubMed ID: 27835982)
1. Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.
Saito Z; Kaneko Y; Kinoshita A; Kurita Y; Odashima K; Horikiri T; Yoshii Y; Seki A; Seki Y; Takeda H; Kuwano K
BMC Infect Dis; 2016 Nov; 16(1):668. PubMed ID: 27835982
[TBL] [Abstract][Full Text] [Related]
2. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
3. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
[TBL] [Abstract][Full Text] [Related]
5. Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein.
Hidaka I; Hino K; Korenaga M; Gondo T; Nishina S; Ando M; Okuda M; Sakaida I
Liver Int; 2007 Aug; 27(6):845-53. PubMed ID: 17617128
[TBL] [Abstract][Full Text] [Related]
6. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
7. Is the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment?
Xu L; Zhang F; Xu C; Liu KG; Wu W; Tian YX
Chemotherapy; 2017; 62(5):269-278. PubMed ID: 28490012
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study.
Lang SM; Ortmann J; Rostig S; Schiffl H
Int J Mycobacteriol; 2019; 8(1):89-92. PubMed ID: 30860185
[TBL] [Abstract][Full Text] [Related]
10. Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity.
Sarda P; Sharma SK; Mohan A; Makharia G; Jayaswal A; Pandey RM; Singh S
Indian J Med Res; 2009 Jan; 129(1):64-7. PubMed ID: 19287059
[TBL] [Abstract][Full Text] [Related]
11. Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection.
Fountain FF; Tolley EA; Jacobs AR; Self TH
Am J Med Sci; 2009 May; 337(5):317-20. PubMed ID: 19295414
[TBL] [Abstract][Full Text] [Related]
12. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Tweed CD; Wills GH; Crook AM; Dawson R; Diacon AH; Louw CE; McHugh TD; Mendel C; Meredith S; Mohapi L; Murphy ME; Murray S; Murthy S; Nunn AJ; Phillips PPJ; Singh K; Spigelman M; Gillespie SH
BMC Med; 2018 Mar; 16(1):46. PubMed ID: 29592805
[TBL] [Abstract][Full Text] [Related]
13. Hepatoprotective Effects of a Proprietary Glycyrrhizin Product during Alcohol Consumption: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
Chigurupati H; Auddy B; Biyani M; Stohs SJ
Phytother Res; 2016 Dec; 30(12):1943-1953. PubMed ID: 27539273
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis.
Shin HJ; Lee HS; Kim YI; Lim SC; Jung JP; Ko YC; Kwon YS
Int J Tuberc Lung Dis; 2014 Mar; 18(3):347-51. PubMed ID: 24670574
[TBL] [Abstract][Full Text] [Related]
15. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.
Genovese MC; Kremer JM; van Vollenhoven RF; Alten R; Scali JJ; Kelman A; Dimonaco S; Brockwell L
Arthritis Rheumatol; 2017 Sep; 69(9):1751-1761. PubMed ID: 28597609
[TBL] [Abstract][Full Text] [Related]
16. [Effect of glycyrrhizin on anti-tuberculosis drug-induced hepatitis].
Miyazawa N; Takahashi H; Yoshiike Y; Ogura T; Watanuki Y; Sato M; Kakemizu N; Yamakawa Y; U CH; Goto H; Odagiri S
Kekkaku; 2003 Jan; 78(1):15-9. PubMed ID: 12655701
[TBL] [Abstract][Full Text] [Related]
17. Hepatoprotective effect of Anacyclus pyrethrum Linn. against antitubercular drug-induced hepatotoxicity in SD rats.
Usmani A; Mujahid M; Khushtar M; Siddiqui HH; Rahman MA
J Complement Integr Med; 2016 Sep; 13(3):295-300. PubMed ID: 27101559
[TBL] [Abstract][Full Text] [Related]
18. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
[TBL] [Abstract][Full Text] [Related]
19. Hepatotoxicity Due to Antituberculosis Therapy among Paediatric Patients Seen at the University of Ilorin Teaching Hospital, North Central Nigeria.
Aishatu G; Rasheedah I; Wahab J; Sheni M; Damilola O; Adeniyi O
Ethiop J Health Sci; 2017 Mar; 27(2):115-120. PubMed ID: 28579706
[TBL] [Abstract][Full Text] [Related]
20. A descriptive analysis of aspartate and alanine aminotransferase rise and fall following acetaminophen overdose.
Curtis RM; Sivilotti ML
Clin Toxicol (Phila); 2015 Nov; 53(9):849-55. PubMed ID: 26294195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
